ArticleOncogene2000
Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Single-Cell RNA Sequencing Identifies a Distinct Epithelial Subpopulation Driving Resistance to Neoadjuvant Chemoimmunotherapy in Esophageal Squamous Cell Carcinoma.Biological procedures online · 2026Article
- FLI-1 is expressed in a wide variety of hematolymphoid neoplasms: a special concern in the differential diagnosis.Clinical and experimental medicine · 2024Article
- Article
- ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.The Prostate · 2018Article
- Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.Genes & development · 2017Article
- Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression.Cancer research · 2016Article
- Ets-1 global gene expression profile reveals associations with metabolism and oxidative stress in ovarian and breast cancers.Cancer & metabolism · 2013Article
- Role for Ets-2(Thr-72) transcription factor in stage-specific thymocyte development and survival.The Journal of biological chemistry · 2012Article
- Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.PloS one · 2011Article
- Article
- Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc.The Journal of biological chemistry · 2008Article
- Review
- Novel role for PDEF in epithelial cell migration and invasion.Cancer research · 2005Article
- Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells.Nucleic acids research · 2004Article
- Ets2-dependent stromal regulation of mouse mammary tumors.Molecular and cellular biology · 2003Article
- Increased zinc finger protein zFOC1 transcripts in gastric cancer compared with normal gastric tissue.Molecular pathology : MP · 2003Article
- Overexpression of ETS2 in human esophageal squamous cell carcinoma.World journal of gastroenterology · 2003Article
- Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter.Nucleic acids research · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The Ets family of transcription factors are important downstream targets in cellular transformation, as altering Ets activity has been found to reverse the transformed phenotype of Ras transformed mouse fibroblasts and of several human tumor cell lines. To determine whether Ets factors are important targets in the largely uncharacterized aberrant signaling in prostate cancer, we have altered Ets activity in the prostate tumor cell line PPC-1, by stable expression of either full-length Ets2, or a dominant inhibitor of Ets activity, the Ets2 DNA binding domain (Ets2DBD). Analysis of multiple independent clonal cell lines revealed that expression of either Ets2 or the Ets2DBD inhibited the anchorage-independent growth of PPC-1 cells up to 20-fold. In contrast to our previous findings with Ras-transformed NIH3T3 cells, PPC-1 cell lines expressing either Ets2 or the EtsDBD exhibited slower attached cell growth, increased Ets-dependent gene expression, and up to a 10-fold increase in apoptotic cell death. The p21cip gene was identified as a potential target of altered Ets signaling. Interestingly, the two distinct Ets2 constructs had strikingly different effects on in vitro invasiveness. Expression of the Ets2DBD almost completely blocked PPC-1 cell invasion through Matrigel, whereas over-expression of full-length Ets2 did not inhibit invasion. Overall, these results demonstrate that the balance of Ets factor activity can regulate multiple aspects of the transformed phenotype of PPC-1 prostate tumor cells, including anchorage-independent growth, survival, and invasiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.